What Is the Future of the Newborn Screening Program Market? 2025–2032 Outlook According to a newly published market research report by 24LifeSciences, global newborn screening program market was valued at USD 629 million in 2024 and is projected to reach USD 750 million by 2032, growing at a compound annual growth rate (CAGR) of 2.6% during the forecast period. Newborn screening represents a cornerstone of pediatric preventive healthcare, involving the systematic testing of infants shortly after birth to identify congenital disorders that may not be immediately apparent. These programs utilize a heel-prick blood sample to detect conditions such as hypothyroidism, phenylketonuria, galactosemia, and sickle cell disease through advanced methodologies like tandem mass spectrometry and enzymatic assays. The fundamental purpose is to enable timely medical interventions that can prevent severe health complications, disability, or even death, thereby significantly improving long-term outcomes for affected children. While global adoption continues to grow, propelled by rising awareness and mandatory policies in numerous countries, the market still contends with challenges including regional disparities in implementation and the ongoing need for technological advancement in diagnostic capabilities. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/2231/newborn-screening-program-market

PKU Market to Grow at 11% CAGR Through 2032 – Emerging Treatments According to a newly published market research report by 24LifeSciences, global Phenylketonuria (PKU) market was valued at USD 1.35 billion in 2024 and is projected to reach USD 2.77 billion by 2031, growing at a compound annual growth rate (CAGR) of 11.0% during the forecast period 2025–2031. Phenylketonuria (PKU) is a rare inherited metabolic disorder characterized by a deficiency of the enzyme phenylalanine hydroxylase (PAH), which is essential for metabolizing the amino acid phenylalanine. This deficiency leads to a dangerous accumulation of phenylalanine in the blood, which, if left untreated, can cause severe and irreversible neurological damage, intellectual disability, seizures, and behavioral issues. Lifelong management through a strict phenylalanine-restricted diet remains the foundation of treatment, though pharmaceutical options have expanded significantly in recent years. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6724/phenylketonuria-pku-market-market